Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Vryalar

- PMLiVE

New iPad app helps schizophrenia patients

Research shows the app ‘Wizard’ could aid memory and independence

- PMLiVE

Teva buys Allergan generics unit for $40.5bn

Will now drop its six-month pursuit of Mylan

- PMLiVE

NICE backs Bayer’s Eylea in diabetic eye condition

TheInstitute also recommends Allergan's Ozurdex in final guidance

Allergan logo

Allergan stumps up $375m for bolt-on acquisitions

Firm has recently added two migraine drugs and Oculeve to its portfolio

Allergan logo

Allergan inks $2.1bn deal to buy cosmetic drug firm Kythera

Company will add Kythera’s double chin therapy Kybella to its portfolio

Allergan logo

More waiting for Allergan and Gedeon Richter’s antipsychotic

FDA announced it will take another three months to review cariprazine for schizophrenia

- PMLiVE

FDA approves J&J’s schizophrenia drug Invega Trinza

New version of Invega is the first treatment for the condition to require only four doses a year

- PMLiVE

Kythera bags FDA approval for double chin therapy

Comes as cosmetics industry sees major growth

- PMLiVE

Actavis completes $70.5bn Allergan acquisition

Finalisation comes after bidding war with deal-hungry Valeant

- PMLiVE

NICE recommends Ozurdex for diabetic eye condition

Draft guidance cites implant as option for patients with diabetic macular oedema

- PMLiVE

J&J gets quicker review for schizophrenia depot in US

Could be ready to market by the middle of this year

- PMLiVE

Actavis to buy Allergan for $66bn

Ends Valeant’s pursuit of Botox maker

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links